Skip to main content
eScholarship
Open Access Publications from the University of California

A genome sequencing program for novel undiagnosed diseases.

  • Author(s): Bloss, Cinnamon S
  • Zeeland, Ashley A Scott-Van
  • Topol, Sarah E
  • Darst, Burcu F
  • Boeldt, Debra L
  • Erikson, Galina A
  • Bethel, Kelly J
  • Bjork, Robert L
  • Friedman, Jennifer R
  • Hwynn, Nelson
  • Patay, Bradley A
  • Pockros, Paul J
  • Scott, Erick R
  • Simon, Ronald A
  • Williams, Gary W
  • Schork, Nicholas J
  • Topol, Eric J
  • Torkamani, Ali
  • et al.
Abstract

The Scripps Idiopathic Diseases of Man (IDIOM) study aims to discover novel gene-disease relationships and provide molecular genetic diagnosis and treatment guidance for individuals with novel diseases using genome sequencing integrated with clinical assessment and multidisciplinary case review. Here we describe the operational protocol and initial results of the IDIOM study.A total of 121 cases underwent first-tier review by the principal investigators to determine whether the primary inclusion criteria were satisfied, 59 (48.8%) underwent second-tier review by our clinician-scientist review panel, and 17 patients (14.0%) and their family members were enrolled.60% of cases resulted in a plausible molecular diagnosis, and 18% of cases resulted in a confirmed molecular diagnosis. Two of three confirmed cases led to the identification of novel gene-disease relationships. In the third confirmed case a previously described but unrecognized disease was revealed. In all three confirmed cases a new clinical management strategy was initiated based on the genetic findings.Genome sequencing provides tangible clinical benefit for individuals with idiopathic genetic disease, not only in the context of molecular genetic diagnosis of known rare conditions but also in cases where prior clinical information regarding a new genetic disorder is lacking.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View